Cost-effectiveness of one-time genetic testing to minimize lifetime adverse drug reactions

Reportedly the first study of its kind, Alagagoz, Durham and Kasirajan bring forth conclusive evidence for the benefit of one-time genetic testing over the life time of patients from a certain demographic concentration. Not only benefit derived in increased personalized health care because of the guide of their genetics, but also that of lifetime cost, reflected in the prevention of ADRs (adverse drug reactions). Continue on to the primary literature below from the Pharmacogenomics Journal from